NCT02340481 arm group f31ab57da8a191f0455bba91bd68a90a [clinicaltrials_resource:NCT02340481/arm-group/f31ab57da8a191f0455bba91bd68a90a]
Loperamide hydrochloride [clinicaltrials_resource:405fae0f28ef4c9f8d70da237eb3d3da]Loperamide hydrochloride + simethicone chewable placebo tablet [clinicaltrials_resource:78e75689ad451ccb81d547a53b67622d]Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence [clinicaltrials:NCT02340481]
arm group [clinicaltrials_vocabulary:arm-group]
NCT02340481 arm group f31ab57da8a191f0455bba91bd68a90a [clinicaltrials_resource:NCT02340481/arm-group/f31ab57da8a191f0455bba91bd68a90a]
Bio2RDF identifier
NCT02340481/arm-group/f31ab57da8a191f0455bba91bd68a90a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 1ab57da8a191f0455bba91bd68a90a
description [clinicaltrials_vocabulary:description]
Participant will take 2 lopera ...... 4-hour period) up to 48 hours.
identifier
clinicaltrials_resource:NCT02340481/arm-group/f31ab57da8a191f0455bba91bd68a90a
title
NCT02340481 arm group f31ab57da8a191f0455bba91bd68a90a
@en
type
label
NCT02340481 arm group f31ab57d ...... ab57da8a191f0455bba91bd68a90a]
@en